C. Su

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma

Kueian Chen, W. Jeng, Chen-Chun Lin, 2022, Cancer medicine.

Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.

J. Hsieh, Chen-Chun Lin, W. Teng, 2022, American journal of cancer research.

Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma

D. Tsan, Eric Yi-Liang Shen, Po-Ting Lin, 2024, The oncologist.

Adding nutritional status to the original BCLC stage improves mortality prediction for hepatocellular carcinoma patients in HBV-endemic regions.

Chun-Yi Tsai, Chen-Chun Lin, W. Teng, 2023, American journal of cancer research.